Compare VOYA & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | DVA |
|---|---|---|
| Founded | 1975 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 10.1B |
| IPO Year | N/A | 2002 |
| Metric | VOYA | DVA |
|---|---|---|
| Price | $68.74 | $150.10 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $85.90 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 974.8K | 749.5K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $4.27 | $3.80 |
| Revenue Next Year | $4.98 | $3.04 |
| P/E Ratio | ★ $12.00 | $15.25 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $52.43 | $101.00 |
| 52 Week High | $79.99 | $159.42 |
| Indicator | VOYA | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 55.72 |
| Support Level | $66.17 | $146.00 |
| Resistance Level | $76.11 | $150.69 |
| Average True Range (ATR) | 2.41 | 4.46 |
| MACD | 0.11 | -1.65 |
| Stochastic Oscillator | 49.62 | 29.07 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.